Cytosorbents Corp. (NASDAQ: CTSO) Expected to Announce Doubling in Sales for 2016
Cytosorbents Corp. (NASDAQ: CTSO), a critical care-focused immunotherapy company engaged in the research, development, and commercialization of medical devices, most prominently its platform blood purification technology that incorporates a proprietary adsorbent polymer technology, recently pre-announced unaudited results (http://nnw.fm/P4Yaz) for fiscal 2016 ahead of its Form 10-K filing. Cytosorbents expects to announce between $8.1 and $8.3 million in Cytosorb sales for the whole of 2016. This equates to more than double the total from the previous year. Cytosorb is the company’s flagship product, a blood filter that helps treat deadly inflammation in critically-ill and cardiac surgery patients across the globe. In…